Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a global prevalence exceeding 2% and rising progressively due to population aging. Beyond pharmacological treatment with antiarrhythmics and anticoagulants, catheter ablation has established itself as the most effective rhythm control strategy, with indications that expand with each guideline update. In 2026, the debate is no longer whether to ablate, but when and with which technique.
Ablation rationale: the role of pulmonary veins
90-95% of triggering foci for paroxysmal AF originate in the pulmonary veins (PV), specifically at the pulmonary vein-left atrium junction. Electrical isolation of all four pulmonary veins (PVAI) is therefore the fundamental anatomical target of all AF ablation. The technique can be achieved via radiofrequency (RF) energy, cryoballoon ablation, or, more recently, pulsed field ablation (PFA).
Cryoablation versus radiofrequency: comparative evidence
The FIRE AND ICE trial (2016, n=762) demonstrated non-inferiority of second-generation cryoballoon versus point-by-point RF for paroxysmal AF. Cryoablation is faster (30-40 minutes shorter procedure time) with a shorter learning curve, but RF with contact-force catheter offers greater versatility for complex atrial substrate.
The STOP AF FIRST trial (2021) established cryoablation superiority over antiarrhythmic drug therapy in patients with newly diagnosed paroxysmal AF without prior pharmacological treatment, with 12-month freedom from recurrence of 75% versus 45% in the pharmacological arm.
Pulsed Field Ablation: the technological revolution
Pulsed field ablation (PFA) represents the greatest technological advance in AF ablation since cryoablation. It uses high-intensity, short-duration electric fields to produce irreversible electroporation and selective cell death in cardiomyocytes, sparing adjacent tissue (esophagus, phrenic nerve, pulmonary veins) due to their different electroporation thresholds.
Data from the MANIFEST-PF registry (1,758 patients, 24 European centers) with the Farapulse system show PV isolation rates of 99.2% with a mean procedure time of 58 minutes and a major complication rate of 0.6%, lower than historical RF and cryoablation series. The absence of atrioesophageal fistula in series published through 2026 is the most relevant safety finding.
Expanded indications: persistent AF and AF in heart failure
ESC 2020 guidelines already recommended ablation for symptomatic paroxysmal AF after at least one antiarrhythmic drug. In 2026, the trend is toward ablation as a first-line strategy in specific profiles:
- Newly diagnosed paroxysmal AF: strong evidence for early ablation before irreversible atrial remodeling
- AF with heart failure and reduced EF: CASTLE-AF trial demonstrated 38% reduction in all-cause mortality and 44% reduction in HF hospitalization with ablation versus medical therapy
